VISEN Pharmaceuticals operates as a biopharmaceutical company. The company is headquartered in Suzhou, Jiangsu and currently employs 54 full-time employees. The company went IPO on 2025-03-21. The firm's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The firm is in the late stage of research and development, and its products are close to commercialization.
02561.HK stock price ended at $34.4 on 星期二, after rising 0.00%
On the latest trading day Jan 20, 2026, the stock price of 02561.HK rose by 0.00%, climbing from $33.30 to $34.40. During the session, the stock saw a volatility of 3.30%, with prices oscillating between a daily low of $33.30 and a high of $34.40. Notably, trading volume dropped by -- shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 2.3K shares were traded, equating to a market value of approximately $3.9B.